Murat O. Arcasoy
Expertise in
15
conditions

Dr. Murat O. Arcasoy

Hematology
Duke University Hospital
1926 Good Hope Rd, 
Enola, PA 
Accepting New Patients
Expertise in
15
conditions
Duke University Hospital
1926 Good Hope Rd, 
Enola, PA 

Overview

Murat Arcasoy is a Hematologist practicing medicine in Enola, Pennsylvania.

Dr. Arcasoy is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 6 clinical trials. Dr. Arcasoy is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

Duke University Hospital
1926 Good Hope Rd, Enola, PA 17025
Other Locations
Durham VA Medical Center
508 Fulton St, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

28 Total Publications

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Journal: Clinical advances in hematology & oncology : H&O
Published: March 06, 2024
Similar Doctors
Expertise in
15
conditions
Dr. Efrat Dotan
Hematology | Oncology
Expertise in
15
conditions
Dr. Efrat Dotan
Hematology | Oncology
Referral may be required
Before you request

LG Health Physicians Hematology And Medical Oncology

2102 Harrisburg Pike, 
Lancaster, PA 
 (36.4 miles away)
717-544-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Efrat Dotan is a Hematologist and an Oncologist practicing medicine in Lancaster, Pennsylvania. Dr. Dotan is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Dotan is board certified in Medical Oncology, 2010. Dr. Dotan is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Reading Hospital

420 S 5th Ave Bldg N, 
Reading, PA 
 (54.9 miles away)
484-628-0900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Radhakrishnan Ramchandren is a Hematologist practicing medicine in Reading, Pennsylvania. Dr. Ramchandren is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ramchandren is currently accepting new patients.

Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (16.3 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Jonathan Bernstein is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Bernstein is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Spontaneous Urticaria (CSU), Hemophilia A, Mast Cell Activation Syndrome (MCAS), and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Frequently Asked Questions about Dr. Murat O. Arcasoy

How do I make an appointment with Dr. Murat O. Arcasoy?

You can book an appointment with Dr. Murat O. Arcasoy by calling their office at 919-684-8111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Murat O. Arcasoy a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Murat O. Arcasoy is classified as an Distinguished expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Murat O. Arcasoy specialize in?

While Dr. Murat O. Arcasoy is a Hematology, they have specific expertise in Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Murat O. Arcasoy participate in research or clinical trials?

Yes. Dr. Murat O. Arcasoy has published 28 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Dr. Murat O. Arcasoy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Murat O. Arcasoy accept my insurance?

Dr. Murat O. Arcasoy accepts most major insurance plans, including Humana and Piedmont. We recommend calling the office directly at 919-684-8111 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arcasoy's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile